Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174861 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 609
- Enrollment target
NCT02174861: Completed Phase 2 study, sponsored by Amgen.
NCT02174861 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 609 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (358% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02174861, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 609 participants
- Enrollment target
Study Summary
To assess the long-term safety and efficacy of erenumab.
Primary Outcome
Adverse events (AEs) were graded for severity using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, where Grade 1 = mild AE, asymptomatic or mild symptoms; Grade 2 = Moderate AE; Grade 3 = Severe or medically significant but not immediately life-threatening; Grade 4 = Life-threatening consequences; urgent intervention indicated; Grade 5 = Death related to AE.
Interventions
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2014-06-30 |
| Est. Completion | 2017-05-26 |
| Phase | Phase 2 |
What the finished NCT02174861 record still lists
NCT02174861 is an interventional study that assigns participants to a tested intervention. The registered 609 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (358% higher).
The record links to 0 conditions, and to 1 intervention - of which Erenumab is the first listed.
NCT02174861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02174861 about?
NCT02174861 is a clinical study titled "A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.". To assess the long-term safety and efficacy of erenumab.
What is the current status of trial NCT02174861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 609 participants. The study started on 2014-06-30. Estimated completion is 2017-05-26.
What interventions are being tested in trial NCT02174861?
The interventions under investigation include: Erenumab (DRUG).
Who is sponsoring clinical trial NCT02174861?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02174861's enrollment target sits among peer trials
609 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT05838638 · 610 participants · NA
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
- NCT07075718 · 610 participants · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI